Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 11:18 PM
Ignite Modification Date: 2025-12-24 @ 11:18 PM
NCT ID: NCT01311856
Eligibility Criteria: Inclusion Criteria: 1. Diagnosis of either loco-regional breast cancer (Stages 0 - IIIA), colon cancer (Stages I - II), endometrial cancer (Stages I - IIIa) or prostate cancer (Stages I - II); 2. No history of other cancers (excluding non-melanoma skin cancer); 3. Age 18 years of age or older; 4. BMI greater than or equal to 25; 5. Has access to a computer with high-speed internet; 6. Has access to a telephone for possible multiple counseling sessions; 7. Living in the Houston area (Harris county or a contiguous county); 8. Has agreed in the protocol 2009-0544 survey to be re-contacted about studies (for breast, prostate, and colon cancer survivors), or is an endometrial cancer survivor seen seen by an MD Anderson gynecologic oncologist at MD Anderson or an outreach site; 9. Able to come to MD Anderson for assessments at baseline and six-month intervals; 10. Has completed primary cancer treatment and is at least 3 months from surgery (if elected); 11. Able to read and speak English; and 12. Able to provide informed consent. Exclusion Criteria: 1. Have pre-existing medical conditions that preclude adherence to an unsupervised exercise program or a low-fat, high fruit and vegetable (F\&V) diet; 2. Persons using walker or wheelchair/scooter; 3. Women who are pregnant; and 4. Patients that are identified as having metastatic disease at the time of recruitment.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Study: NCT01311856
Study Brief:
Protocol Section: NCT01311856